All-Oral Direct-Acting Agent Daclatasvir Plus Asunaprevir for Chronic Genotype 1b Hepatitis C Virus Infection Patients: Real-World Experience of Virologic Response and Side Effects
碩士 === 中山醫學大學 === 醫學研究所 === 104 === Introduction: All-oral direct-acting agent dual therapy with Daclatasvir plus Asunaprevir (DCV+ASV) achieved high sustained virological responses (SVR) in genotype 1b (GT-1b) HCV patients in the HALLMARK-DUAL1 study and Phase 3 Japanese study2,3. DCV + ASV is appr...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2016
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/2m99sr |